AGR2 associates with HER2 expression predicting poor outcome in subset of estrogen receptor negative breast cancer patients

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F17%3A00077857" target="_blank" >RIV/00209805:_____/17:00077857 - isvavai.cz</a>

Výsledek na webu

<a href="https://linkinghub.elsevier.com/retrieve/pii/S0014-4800(16)30276-3" target="_blank" >https://linkinghub.elsevier.com/retrieve/pii/S0014-4800(16)30276-3</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.yexmp.2017.02.016" target="_blank" >10.1016/j.yexmp.2017.02.016</a>

Jazyk výsledku

angličtina

Název v původním jazyce

AGR2 associates with HER2 expression predicting poor outcome in subset of estrogen receptor negative breast cancer patients

Popis výsledku v původním jazyce

Expression of the AGR2 oncogenewas shown to be associated with estrogen receptor positive tumors. This gene contributes to enhanced cellular proliferation, drug resistance, metastasis development and may also serve as a predictor of poor prognosis. However, our analysis of AGR2 expression in a subset of estrogen-receptor negative tumors revealed that AGR2 could also be upregulated in hormone-independent manner. AGR2 expression was shown to be significantly increased in HER2 positive breast tumors on both the mRNA and the protein level. Moreover, in a subset of estrogen- and progesterone-receptor negative and simultaneously HER2-positive cases, increased AGR2 expression significantly correlated with worse patient prognosis. Subsequent analysis of independent data sets either collected in our institute or obtained from Oncomine cancer microarray database confirmed all these findings.

Název v anglickém jazyce

AGR2 associates with HER2 expression predicting poor outcome in subset of estrogen receptor negative breast cancer patients

Popis výsledku anglicky

Expression of the AGR2 oncogenewas shown to be associated with estrogen receptor positive tumors. This gene contributes to enhanced cellular proliferation, drug resistance, metastasis development and may also serve as a predictor of poor prognosis. However, our analysis of AGR2 expression in a subset of estrogen-receptor negative tumors revealed that AGR2 could also be upregulated in hormone-independent manner. AGR2 expression was shown to be significantly increased in HER2 positive breast tumors on both the mRNA and the protein level. Moreover, in a subset of estrogen- and progesterone-receptor negative and simultaneously HER2-positive cases, increased AGR2 expression significantly correlated with worse patient prognosis. Subsequent analysis of independent data sets either collected in our institute or obtained from Oncomine cancer microarray database confirmed all these findings.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Experimental and molecular pathology

ISSN

0014-4800

e-ISSN

—

Svazek periodika

102

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

4

Strana od-do

"280–283"

Kód UT WoS článku

000403040200017

EID výsledku v databázi Scopus

2-s2.0-85014107239